Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 797-804

  Kazutoshi, O T A ^a   Fujimori, Hiromi ^a   Ueda, Mitsuharu ^a   Jono, Hirofumi ^a   Shinriki, Satoru ^a   Ota, Tomoko ^a   Sueyoshi, Takanao ^a   Taura, Manabu ^b   Taguma, Ayaka ^b   Kai, Hirofumi ^b   Shinohara, Masanori ^a   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Midkine; Oral squamous cell carcinoma; p53; Prognosis

Indexed keywords

MIDKINE; PROTEIN P53;

ADULT; ARTICLE; CELL CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TONGUE CARCINOMA;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYTOKINES; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL RATE; TIME FACTORS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956509716     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000729     Document Type: Article

References (56)

1. Casiglia J and Woo SB: A comprehensive review of oral cancer. Gen Dent 49: 72-82, 2001.
2. Beenken SW and Urist MM: Head and neck tumors. In: Current Surgical Diagnosis & Treatment. Lange Medical Books/McGraw-Hill, New York, 2003.
3. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C: Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 5: 2082-2088, 1999.
4. Pfister C, Larue H, Moore L, et al: Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes. Int J Cancer 89: 100-104, 2000.
5. Koontongkaew S, Chareonkitkajorn L, Chanvitan A, Leelakriangsak M and Amornphimoltham P: Alterations of p53, pRb, cyclin D(1) and cdk4 in human oral and pharyngeal squamous cell carcinomas. Oral Oncol 36: 334-339, 2000.
6. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319: 1-11, 2004.
7. Reuter CW, Morgan MA and Eckardt A: Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br J Cancer 96: 408-416, 2007. (Pubitemid 46215210)
8. Kadomatsu K, Tomomura M and Muramatsu T: cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in midgestation period of mouse embryogenesis. Biochem Biophys Res Commun 151: 1312-1318, 1988.
9. Garver RI Jr, Chan CS and Milner PG: Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 9: 463-466, 1993.
10. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR and Milner PG: Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 74: 1584-1590, 1994.
11. Aridome K, Tsutsui J, Takao S, et al: Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 86: 655-661, 1995.
12. Ye C, Qi M, Fan QW, et al: Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 79: 179-184, 1999.
13. Miyauchi M, Shimada H, Kadomatsu K, et al: Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 90: 469-475, 1999.
14. Kato M, Shinozawa T, Kato S, Awaya A and Terada T: Increased midkine expression in hepatocellular carcinoma. Arch Pathol Lab Med 124: 848-852, 2000.
15. Kato M, Maeta H, Kato S, Shinozawa T and Terada T: Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol 13: 1060-1065, 2000.
16. Konishi N, Nakamura M, Nakaoka S, et al: Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 57: 253-257, 1999. (Pubitemid 29481700)
17. Maeda S, Shinchi H, Kurahara H, et al: Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 97: 405-411, 2007.
18. Nakagawara A, Milbrandt J, Muramatsu T, et al: Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 55: 1792-1797, 1995.
19. Mishima K, Asai A, Kadomatsu K, et al: Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 233: 29-32, 1997. (Pubitemid 27402545)
20. Kaifi JT, Fiegel HC, Rafnsdottir SL, et al: Midkine as a prognostic marker for gastrointestinal stromal tumors. J Cancer Res Clin Oncol 133: 431-435, 2007.
21. Ota K, Fujimori H, Ueda M, et al: Midkine as a prognostic biomarker in oral squamous cell carcinoma. Br J Cancer 99: 655-662, 2008.
22. Kato K, Kawashiri S, Tanaka A, et al: Predictive value of measuring p53 labeling index at the invasive front of oral squamous cell carcinomas. Pathol Oncol Res 14: 57-61, 2008.
23. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
24. Sobin LH and Wittekind C: TNM classification of malignant tumours. 6th edition. Wiley-Liss, New York, 2002.
25. Tamura T, Aoyama N, Saya H, et al: Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11: 1939-1946, 1995.
26. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M and Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an HSC70-p53 complex with an altered halflife. Mol Cell Biol 8: 531-539, 1988.
27. Iggo R, Gatter K, Bartek J, Lane D and Harris AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990.
28. Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T and Kim SU: Retinoic acid responsive gene product, midkine, has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res 35: 530-539, 1993. (Pubitemid 23215704)
29. Owada K, Sanjo N, Kobayashi T, et al: Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 73: 2084-2092, 1999.
30. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T and Kadomatsu K: Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bcl-2 expression by midkine. J Biochem 127: 269-277, 2000.
31. Muramatsu H and Muramatsu T: Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun 177: 652-658, 1991.
32. Muramatsu H, Shirahama H, Yonezawa S, Maruta H and Muramatsu T: Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol 159: 392-402, 1993.
33. Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S and Muramatsu T: Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 122: 453-458, 1997.
34. Maeda N, Ichihara-Tanaka K, Kimura T, Kadomatsu K, Muramatsu T and Noda M: A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin-binding growth factor midkine. Involvement of arginine 78 of midkine in the high affinity binding to PTPzeta. J Biol Chem 274: 12474-12479, 1999. (Pubitemid 129518013)
35. Horiba M, Kadomatsu K, Nakamura E, et al: Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 105: 489-495, 2000.
36. Ruan M, Ji T, Wu Z, Zhou J and Zhang C: Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 36: 159-164, 2007.
37. Shimada H, Nabeya Y, Tagawa M, et al: Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 94: 628-632, 2003. (Pubitemid 36975019)
38. Tanabe K, Matsumoto M, Ikematsu S, et al: Midkine and its clinical significance in endometrial carcinoma. Cancer Sci 99: 1125-1130, 2008.
39. Mirkin BL, Clark S, Zheng X, et al: Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene 24: 4965-4974, 2005. (Pubitemid 41129100)
40. Kang HC, Kim IJ, Park JH, et al: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 10: 272-284, 2004.
41. Huncharek M, Kupelnick B, Geschwind JF and Caubet JF: Prognostic significance of p53 mutations in non-small cell lung cancer: A meta-analysis of 829 cases from eight published studies. Cancer Lett 153: 219-226, 2000. (Pubitemid 30209865)
42. Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: A meta-analysis. Clin Cancer Res 6: 4055-4063, 2000.
43. Steels E, Paesmans M, Berghmans T, et al: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719, 2001. (Pubitemid 33040631)
44. Pharoah PD, Day NE and Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: A meta-analysis. Br J Cancer 80: 1968-1973, 1999.
45. Adachi Y, Matsubara S, Pedraza C, et al: Midkine as a novel target gene for the Wilms' tumor suppressor gene (wt1). Oncogene 13: 2197-2203, 1996.
46. Uehara K, Matsubara S, Kadomatsu K, Tsutsui J and Muramatsu T: Genomic structure of human midkine (MK), a retinoic acid-responsive growth/ differentiation factor. J Biochem 111: 563-567, 1992.
47. You Z, Dong Y, Kong X, Beckett LA, Gandour-Edwards R and Melamed J: Midkine is a NF-kappaB-inducible gene that supports prostate cancer cell survival. BMC Med Genomics 1: 6, 2008.
48. Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC and Whitsett JA: Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem 279: 37124-37132, 2004.
49. Reynolds PR, Mucenski ML and Whitsett JA: Thyroid transcription factor (TTF)-1 regulates the expression of midkine (MK) during lung morphogenesis. Dev Dyn 227: 227-237, 2003.
50. Yu L, Ugai S, J OW, et al: Cell growth- and p53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cells. Oncol Rep 10: 1301-1305, 2003.
51. Yu ZW, Zhao P, Liu M, et al: Reversal of 5-flourouracil resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells. World J Gastroenterol 10: 1979-1983, 2004.
52. Eisold S, Linnebacher M, Ryschich E, et al: The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 10: 3583-3589, 2004. (Pubitemid 39619273)
53. Seth P, Katayose D, Li Z, et al: A recombinant adenovirus expressing wild-type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers. Cancer Gene Ther 4: 383-390, 1997.
54. Gurnani M, Lipari P, Dell J, Shi B and Nielsen LL: Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother Pharmacol 44: 143-151, 1999.
55. Fujiwara T, Tanaka N, Kanazawa S, et al: Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 24: 1689-1699, 2006.
56. Nemunaitis J, Swisher SG, Timmons T, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18: 609-622, 2000.